Gilead Sciences (GILD) Cash from Investing Activities (QoQ) (2009 - 2026)

Gilead Sciences (GILD) Cash from Investing Activities (QoQ) (2009 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 196.46%
Dec 31, 2025 -329.74%
Sep 30, 2025 79.82%
Jun 30, 2025 -409.88%
Mar 31, 2025 -84.44%
Dec 31, 2024 68.31%
Sep 30, 2024 -131.27%
Jun 30, 2024 86.09%
Mar 31, 2024 -203.58%
Dec 31, 2023 -217.47%
Sep 30, 2023 52.59%
Jun 30, 2023 41.53%
Mar 31, 2023 -120.27%
Dec 31, 2022 47.41%
Sep 30, 2022 -131.49%
Jun 30, 2022 71.21%
Mar 31, 2022 -284.89%
Dec 31, 2021 -18.80%
Sep 30, 2021 59.45%
Jun 30, 2021 71.74%